Skip to main content

Table 2 Adjusted hazards ratios and 95% confidence intervals for the risk of ischemic stroke and hemorrhagic stroke across terminal nodes in the Kailuan I participants with low-density lipoprotein cholesterol concentrations < 70 mg/dL

From: The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations < 70 mg/dL

 

Ischemic stroke, HR (95%CI)

Node1

Node2

Node3

Node4

Node5

Node6

Node7

Node8

Node9

Case/person-years

15/28,515

37/15,483

78/14,743

60/10,818

8/1026

119/12,021

10/547

53/2553

8/143

LDL-C ± SD, mg/dL

56.8 ± 10.9

57.3 ± 10.8

64.6 ± 3.03

57.7 ± 8.76

55.6 ± 11.9

50.1 ± 6.48

19.2 ± 8.90

20.3 ± 8.53

20.6 ± 9.63

Multivariate modela

1.00 (reference)

3.73 (2.01, 6.92)

7.07 (3.98, 12.6)

7.38 (4.05, 13.4)

8.44 (3.04, 23.4)

13.0 (7.41, 22.7)

20.8 (7.86, 54.8)

23.1 (12.4, 43.1)

76.3 (30.2, 192.7)

Excluding eGFR < 60 ml/min/1.73 m2

1.00 (reference)

3.60 (1.94, 6.70)

6.06 (3.37, 10.9)

7.10 (3.85, 13.1)

8.86 (3.19, 24.6)

12.8 (7.30, 22.4)

18.9 (6.69, 53.4)

24.6 (13.1, 46.2)

62.2 (23.3, 166.3)

Excluding Framingham risk score > 30%

1.00 (reference)

3.82 (2.02, 7.23)

6.41 (3.38, 12.1)

6.71 (3.29, 13.7)

10.4 (3.74, 29.2)

12.3 (6.74, 22.4)

24.2 (6.74, 86.6)

23.3 (11.2, 48.1)

76.8 (24.7, 238.3)

Excluding BMI < 18.5 kg/m2

1.00 (reference)

3.75 (2.02, 6.94)

7.01 (3.94, 12.5)

7.51 (4.12, 13.7)

8.37 (3.02, 23.2)

13.0 (7.45, 22.8)

21.9 (8.29, 57.9)

23.1 (12.4, 43.1)

74.5 (29.5, 188.2)

Excluding blood pressure-lowering drugs

1.00 (reference)

3.48 (1.85, 6.56)

6.49 (3.50, 12.0)

7.24 (3.88, 13.5)

9.26 (3.32, 25.8)

11.0 (6.10, 19.8)

22.0 (8.24, 59.0)

22.3 (11.5, 43.2)

52.1 (16.8, 161.5)

Excluding glucose-lowering drugs

1.00 (reference)

3.69 (1.98, 6.87)

6.92 (3.87, 12.4)

7.81 (4.27, 14.3)

9.35 (3.36, 26.0)

13.1 (7.49, 23.0)

18.0 (6.39, 50.7)

21.8 (11.6, 40.9)

63.1 (23.7, 168.0)

 

Hemorrhagic stroke, HR (95%CI)

Node1

Node2

Node3

Node4

Node5

Node6

Case/person-years

13/41,704

13/4435

19/10,553

75/27,377

12/2102

13/739

LDL-C ± SD, mg/dL

59.3 ± 7.25

28.9 ± 9.75

58.8 ± 7.51

57.8 ± 8.82

19.9 ± 8.60

20.2 ± 8.03

Multivariate modela

1.00 (reference)

4.40 (2.07, 9.33)

6.59 (3.55, 12.2)

5.41 (2.22, 13.2)

9.74 (3.84, 24.7)

41.7 (17.2, 101.6)

Excluding eGFR < 60 ml/min/1.73 m2

1.00 (reference)

4.58 (2.13, 9.85)

6.55 (3.52, 12.2)

4.68 (1.84, 11.9)

9.98 (3.78, 26.4)

37.5 (15.3, 91.6)

Excluding Framingham risk score > 30%

1.00 (reference)

5.09 (2.02, 12.8)

5.01 (2.51, 9.99)

4.11 (1.52, 11.1)

10.7 (3.25, 35.2)

21.3 (6.86, 65.9)

Excluding BMI < 18.5 kg/m2

1.00 (reference)

4.52 (2.13, 9.59)

6.46 (3.48, 12.0)

4.85 (1.91, 12.3)

9.71 (3.82, 24.7)

42.6 (17.4, 104.2)

Excluding blood pressure-lowering drugs

1.00 (reference)

3.55 (1.57, 8.03)

5.39 (2.78, 10.4)

5.03 (2.05, 12.4)

7.73 (2.60, 23.1)

34.0 (12.8, 89.9)

Excluding glucose-lowering drugs

1.00 (reference)

4.56 (2.14, 9.69)

6.42 (3.44, 12.0)

5.52 (2.26, 13.5)

10.2 (4.00, 25.8)

38.1 (15.2, 95.4)

  1. Abbreviations: HR, hazard ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; eGFR, estimated glomerular filtration rate; BMI, body mass index
  2. aAll models were adjusted for sex (men or women), age (year), physical activity (inactive, moderately active, or vigorously active), smoking and drinking status (never, former, occasional or daily), blood pressure status during follow-up (well-controlled or poorly controlled), blood glucose status during follow-up (well-controlled or poorly controlled), body mass index (kg/m2), urine protein (negative, trace, +, ++, or +++), heart rate (bpm), triglyceride (mg/dL), high-density lipoprotein cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), estimated glomerular filtration rate (ml/min/1.73 m2), and high-sensitivity C-reactive protein (mg/L)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us